AREDS2 and Macular Degeneration: What the Research Actually Shows

What AREDS2 actually is

In one sentence: AREDS2 is the name of a National Eye Institute trial and of the vitamin-and-mineral formula it tested (vitamin C, vitamin E, zinc, copper, lutein and zeaxanthin) to slow macular degeneration in people who already have it at the intermediate stage or beyond.

AREDS2 (Age-Related Eye Disease Study 2) was a large clinical trial funded by the U.S. National Eye Institute, part of the National Institutes of Health. It tested a specific nutrient formula in over 4,000 participants who already had intermediate or advanced age-related macular degeneration (AMD) in at least one eye.

AREDS 1 vs. AREDS 2, briefly: the first trial (published 2001) tested vitamin C, vitamin E, beta-carotene, zinc and copper. AREDS2 (2013) swapped beta-carotene for lutein and zeaxanthin and also tested omega-3 fish oil, which added nothing. Our AREDS vs AREDS2 comparison covers the doses side by side.

It followed an earlier trial, AREDS1, and ran for about five years, with participants tracked for even longer afterward. This is a different level of evidence than most vision supplements have behind them — most are supported by small studies, animal research, or nothing specific to eye disease at all.

AREDS2 study results: what the research shows

The tested formula contains specific, high doses of six nutrients:

• Vitamin C — 500 mg
• Vitamin E — 400 IU
• Zinc — 80 mg (as zinc oxide)
• Copper — 2 mg (added specifically to offset the high zinc dose, which can otherwise cause copper deficiency)
• Lutein — 10 mg
• Zeaxanthin — 2 mg

For people with intermediate AMD, this specific combination, at these specific doses, measurably slowed progression toward vision-threatening advanced disease. That’s a real, replicated, government-funded finding. Supported

The benefit was shown in people who already had intermediate AMD — not as general prevention for people with healthy eyes.

Who should take an AREDS2 supplement

According to the National Eye Institute, the supplements are meant for two groups:

• People with intermediate AMD in one or both eyes. For them, the formula may keep it from turning into late AMD.
• People with late AMD in only one eye. In the NEI’s words, “these supplements may slow down AMD in your other eye.”

They are not recommended as prevention for people with healthy eyes or early AMD, because the trials didn’t show a benefit there. Only a dilated eye exam can tell you which stage you’re at, so this is a conversation to have with an eye doctor before buying anything.

Does AREDS2 help wet macular degeneration?

It isn’t a treatment for wet AMD. Wet AMD, also called advanced neovascular AMD, is a form of late AMD where abnormal blood vessels grow in the back of the eye and damage the macula. It usually causes faster vision loss than the dry form. The NEI lists its treatments as anti-VEGF medicines injected into the eye and, in some cases, photodynamic therapy. A vitamin formula does not replace those.

Where AREDS2 can still matter: if wet AMD has developed in one eye only, the NEI says the supplements may slow AMD in the other eye. That’s a decision to make with the retina specialist who is treating you.

Not a Treatment

What it does not show

• It does not show that this formula prevents AMD from starting in someone who doesn’t have it.
• It does not show benefit for early-stage AMD — the trial specifically enrolled people with intermediate or advanced disease.
• It does not reverse vision loss that has already occurred.
• It does not show benefit for other eye conditions — cataracts, glaucoma, or general “eye strain” — despite how often it’s marketed that way.
• It does not show that lower doses, or the same ingredients mixed with a dozen other things, produce the same effect. The trial tested this exact formula at these exact doses.

If a product markets “AREDS2-inspired” ingredients without matching the actual doses, it’s borrowing credibility from a trial it didn’t replicate. Check The Dose

Why beta-carotene was removed

The original AREDS1 formula included beta-carotene (a form of vitamin A). AREDS2 specifically tested removing it and replacing it with lutein and zeaxanthin — because separate research had linked beta-carotene supplementation to an increased risk of lung cancer in smokers and former smokers.

AREDS2 confirmed that lutein and zeaxanthin worked at least as well, without that risk. Since then, beta-carotene is generally considered the outdated, higher-risk version of this formula — current guidance favors the lutein/zeaxanthin version, especially for anyone who smokes or used to. A 10-year follow-up found beta-carotene nearly doubled lung cancer risk. For the dose-by-dose differences, see AREDS vs AREDS2.